Clinical Trial

A Clinical Study of AFN50 in the Treatment of Autoimmune Diseases

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This study is a single-arm, open-label, single-centre exploratory clinical trial designed to evaluate the safety, tolerability, and preliminary efficacy of AFN50 Injection in adult patients with B-cell-mediated refractory/replapased autoimmune diseases.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-02.
Status change: Not Yet Recruiting → Recruiting 2026-03-09
Trial Details
NCT Number NCT07448298
Lead Sponsor Beijing Boren Hospital
Conditions Relapsed/Refractory Autoimmune Diseases
Enrollment 18 participants
Start Date 2026-03-09
Primary Completion 2028-02-29 (estimated)
Study Completion 2029-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-03-11